Recombinant adenovirus 5 vaccine active in mCRPC
The vaccine was examined in a trial of patients with metastatic castration-resistant prostate cancer who were not responding to available therapies.
Related Articles
Study launches of CAR T therapy for bone metastatic prostate cancer
“We are hopeful that this therapy will help patients with prostate cancer and that this study will be just the first step towards the effective…
Expert discusses meta-analysis of prostate radiotherapy
“In my view, at present in patients that have low-volume oligometastatic de novo metastatic prostate cancer, it’s really an unknown whether comprehensive SBRT or other…
UTv Videos
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Study finds disparities in management of mCSPC
“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for…
Dr. Marhamati on Aquablation in an ambulatory surgery center
“We are very excited here at Potomac Urology to be the first center in the United States, and just the second center internationally, to offer…
212Pb SPECT/CT imaging shows initial benefit, feasibility in mCRPC
“In the future, this imaging technique can help to streamline the drug development process, driving conviction in the agents we bring to larger scale trials,”…
Prostate cancer salvage therapy guideline incorporates PSMA-PET imaging
“A key piece of the guideline is that we need to offer radiation at a PSA of 0.5 ng/mL or lower and maybe even, for…
Cystoscope Preferences and Practices in Urology
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Dr. Foxton on results of drug combination with PSMA agent for prostate cancer
“In terms of the minimal overlapping toxicity, our non-clinical data from the xenograft model showed minimal toxicity with the combination,” says Caroline Foxton, PhD.
Dr. Salari on family history, germline genetic risk in favorable-risk prostate cancer
“What we found is that over a third of patients, 36%, had positive family history of either prostate, breast, or pancreatic cancer. And if you…